• 8569 Citations
  • 29 h-Index
1993 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Pier Francesco Ferrucci is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Melanoma Medicine & Life Sciences
Acute Promyelocytic Leukemia Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Neutrophils Medicine & Life Sciences
Tretinoin Medicine & Life Sciences
Retinoic Acid Receptors Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1993 2019

  • 8569 Citations
  • 29 h-Index
  • 91 Article
  • 3 Letter
  • 2 Comment/debate
  • 1 Short survey

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., Jun 1 2019, In : Nature Medicine. 25, 6, p. 941-946 6 p.

Research output: Contribution to journalLetter

Melanoma
Placebos
Blocking Antibodies
Mitogen-Activated Protein Kinase Kinases
Transaminases

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, S., Hinshelwood, R., Mesnage, S., Cebon, J., Ferrucci, P. F., Aglietta, M., Neyns, B., Chiarion-Sileni, V., Lindsay, C. R., Del Vecchio, M., Linardou, H., Merelli, B., Tonini, G., Atkinson, V., Freivogel, K., Stein, D., Dalland, L., Lau, M., Legenne, P., Queirolo, P. & 1 others, Millward, M., 2019, In : Melanoma Research. 29, 5, p. 527-532 6 p.

Research output: Contribution to journalArticle

Melanoma
Confidence Intervals
Therapeutics
Disease-Free Survival
Fever

A meta-analysis of melanoma risk in industrial workers

on behalf of IMI, the Italian Melanoma Intergroup, Oct 26 2018, In : Melanoma Research.

Research output: Contribution to journalArticle

Meta-Analysis
Chemical Industry
Melanoma
Oils
Confidence Intervals
1 Citation (Scopus)
Conflict of Interest
Melanoma
Survival
Italy
Genes
3 Citations (Scopus)

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Italian Melanoma Intergroup (IMI), Jul 1 2018, In : European Journal of Cancer. 97, p. 59-61 3 p.

Research output: Contribution to journalLetter